Ceva Santé Animale appointed Dr. Steve Chu as its new Vice President, Global Biology Research and Development
Steve will be part of the Biology Management Team and a member of the Ceva Scientific Advisory Board, working at the company’s Biomune Campus in Lenexa, Kansas, USA.
Steve holds a B.S. in Veterinary Medicine, a DVM, an M.S. in Veterinary Virology and a PhD in Microbiology. He was formerly Global Chief Biologics Officer, and Distinguished Research Fellow for Elanco Animal Health. He he’s also held positions at Pfizer, Fort Dodge Animal Health, and Boehringer Ingelheim Animal Health. He’s a member of the American Society for Virology and he has been honored with the CDC Director’s Innovation Award in the category of People Prepared for Emerging Health Threats and Healthy People in a Healthy World for the “Development of an Equine West Nile DNA Vaccine.”
He developed the first West Nile vaccine and also the first DNA vaccine for any species. He’s also co-developed a reverse genetic avian influenza vaccine against highly pathogenic H5N1, and secured the first federally licensed product in the U.S. and European Union.
Related website: CEVA